Advancements in quadruplet regimens for the treatment of multiple myeloma

Niels Van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, discusses advancements in multiple myeloma treatments, highlighting the increased efficacy of quadruplet regimens in both transplant-eligible and transplant-ineligible patients. He emphasizes that recent data from the PERSEUS (NCT03710603) and IMROZ (NCT03319667) trials indicate significant improvements in progression-free survival (PFS) and measurable residual disease (MRD) negativity rates with the addition of agents like daratumumab and isatuximab. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.